Topelia

Topelia is a public, unlisted biotechnology company that has initiated preparations for a Phase 3 trial of its dedicated to Antiviral Triple Therapy (ATT), TPL101, initially targeting coronavirus infections. Building upon their success in commercialising a Triple Therapy for Helicobacter pylori, Topelia's leadership is now developing and commericalising TPL101. Topelia has demonstrated remarkable progress by advancing TPL101 from concept to Phase 3 trials in just over three years. This rapid development underscores the company's commitment to addressing rapid, effective development. Following consultations with regulatory authorities, Topelia has completed two Phase 1 clinical trials and recently initiated a Phase 3 trial for TPL101. Topelia is currently on track to conduct its Phase 3 trial and plans to seek Therapeutic Goods Administration (TGA) approval in the calendar year 2025. TPL101 combines ivermectin and doxycycline—medications with long-standing safety profiles—and zinc in a proprietary fixed-dose combination. By utilising known, regulator-approved active pharmaceutical ingredients (APIs), the development process for TPL101 is faster, more cost-effective, and lower risk. Given its mechanism of action, which targets proteins conserved across various viruses, Topelia plans to investigate TPL101's effectiveness against other respiratory viral infections, including Avian influenza (H5N1) and diseases caused by the Flaviviridae family, such as Dengue, Zika, and Yellow Fever. For more information, visit our website at www.topeliaaustralia.com